Patents Assigned to Proteosys AG
-
Publication number: 20140323408Abstract: Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.Type: ApplicationFiled: May 7, 2014Publication date: October 30, 2014Applicant: PROTEOSYS AGInventor: André SCHRATTENHOLZ
-
Publication number: 20140271922Abstract: The present invention generally relates to the neuroprotective activity of condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as co-medicaments for the prevention and/or treatment of drug-induced neurotoxic effects in general and neurotoxic side effects during cancer treatments with cytostatic drugs such as platinum-derivatives, e.g. cis-, carbo- and oxaliplatin, taxanes, bleomycin, cyclophosphamide and vincristine etc. Further, these compounds have an intrinisic anti-cancer activity on their own due to PARP-1 inhibition, which prevents NADH depletion in oxidative metabolism of healthy cells thus preventing the shift to anoxygenic, glycolytic metabolism present in many types of tumour cells thus eliminating this crucial metabolic advantage favouring tumour growth.Type: ApplicationFiled: October 17, 2013Publication date: September 18, 2014Applicant: PROTEOSYS AGInventor: Andre SCHRATTENHOLZ
-
Publication number: 20140243269Abstract: Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication for effecting neuroprotection in a subject suffering from schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and/or spinal cord injury.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: PROTEOSYS AGInventor: André SCHRATTENHOLZ
-
Publication number: 20140243270Abstract: A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: PROTEOSYS AGInventor: André SCHRATTENHOLZ
-
Patent number: 8466144Abstract: The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.Type: GrantFiled: July 18, 2005Date of Patent: June 18, 2013Assignee: Proteosys AGInventor: André Schrattenholz
-
Patent number: 8409812Abstract: A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.Type: GrantFiled: April 29, 2010Date of Patent: April 2, 2013Assignee: ProteoSys AGInventors: Michael Cahill, André Schrattenholz
-
Patent number: 8377648Abstract: The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.Type: GrantFiled: April 9, 2008Date of Patent: February 19, 2013Assignee: Proteosys AGInventor: Andre Schrattenholz
-
Publication number: 20110294791Abstract: The present invention generally relates to the neuroprotective activity of condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as co-medicaments for the prevention and/or treatment of drug-induced neurotoxic effects in general and neurotoxic side effects during cancer treatments with cytostatic drugs such as platinum-derivatives, e.g. cis-, carbo- and oxaliplatin, taxanes, bleomycin, cyclophosphamide and vincristine etc. Further, these compounds have an intrinsic anti-cancer activity on their own due to PARP-1 inhibition, which prevents NADH depletion in oxidative metabolism of healthy cells thus preventing the shift to anoxygenic, glycolytic metabolism present in many types of tumour cells thus eliminating this crucial metabolic advantage favoring tumour growth.Type: ApplicationFiled: January 13, 2010Publication date: December 1, 2011Applicant: PROTEOSYS AGInventor: Andre Schrattenholz
-
Publication number: 20110263574Abstract: The present invention generally relates to the otoprotective activity of condensed diazepinones, e.g. condensed benzodiazepines such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as medicaments for the prevention and/or treatment of otic diseases, e.g. diseases associated with loss of hearing.Type: ApplicationFiled: January 13, 2010Publication date: October 27, 2011Applicant: PROTEOSYS AGInventor: Andre Schrattenholz
-
Patent number: 8039464Abstract: The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.Type: GrantFiled: July 18, 2005Date of Patent: October 18, 2011Assignee: ProteoSys AGInventor: André Schrattenholz
-
Patent number: 8012697Abstract: The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies.Type: GrantFiled: June 11, 2007Date of Patent: September 6, 2011Assignee: ProteoSys AGInventor: Andre Schrattenholz
-
Patent number: 7998970Abstract: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy.Type: GrantFiled: December 2, 2005Date of Patent: August 16, 2011Assignee: ProteoSys AGInventors: Vukic Soskic, André Schrattenholz
-
Publication number: 20110177536Abstract: The present invention refers to novel antibodies recognizing native annexin A3. These antibodies are suitable for diagnostic and therapeutic applications.Type: ApplicationFiled: September 25, 2009Publication date: July 21, 2011Applicant: PROTEOSYS AGInventors: Slobodan Poznanovic, Gerhard Schwall
-
Publication number: 20110143366Abstract: Presently, the toxicological assessment of chemicals is mainly performed in vivo using a variety of animal species and in addition taking into account human clinical, biochemical, pathological and morphological data. Over the past years it became increasingly clear that some substances are particularly harmful for children and thus there is a focus on the special vulnerability of the developing human brain. Meanwhile there is a recommendation to test substances with a known neurotoxic or teratogenic (in particular a neuroteratogenic) risk additionally for embryotoxicity. Moreover the US Environmental Protection Agency (EPA) requires embryotoxicity tests for pesticides. Further tests are required if substances shall be used as medicaments (S7A Safety Pharmacology Studies for Human Pharmaceuticals, Guidelines of the International Conference on Harmonization, ICH, 2001).Type: ApplicationFiled: June 4, 2009Publication date: June 16, 2011Applicant: PROTEOSYS AGInventor: Andre Schrattenholz
-
Patent number: 7824923Abstract: The invention relates to novel neuregulin-? isoforms associated with neuronal processes.Type: GrantFiled: August 6, 2002Date of Patent: November 2, 2010Assignee: ProteoSys AgInventor: André Schrattenholz
-
Publication number: 20100267051Abstract: A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.Type: ApplicationFiled: April 29, 2010Publication date: October 21, 2010Applicant: ProteoSys AG, a corporation of GermanyInventors: Michael Cahill, Andre Schrattenholz
-
Publication number: 20100256066Abstract: The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.Type: ApplicationFiled: November 17, 2008Publication date: October 7, 2010Applicant: PROTEOSYS AGInventor: André Schrattenholz
-
Publication number: 20100233160Abstract: The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies.Type: ApplicationFiled: June 11, 2007Publication date: September 16, 2010Applicant: PROTEOSYS AGInventor: Andre Schrattenholz
-
Patent number: 7759068Abstract: The present invention relates to the use of an active ingredient and to a method for the prevention or treatment of tumors, the diagnostic detection of disorders associated with these tumors, and pharmaceutical compositions and kits related thereto.Type: GrantFiled: April 15, 2003Date of Patent: July 20, 2010Assignee: Proteosys AGInventors: Michael Cahill, Wojciech Wozny, André Schrattenholz, Helmut Klocker, Hermann Rogatsch
-
Patent number: 7732148Abstract: A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.Type: GrantFiled: May 22, 2006Date of Patent: June 8, 2010Assignee: ProteoSys AGInventors: Michael Cahill, André Schrattenholz